Additional treatment with Liraglutide dramatically reduced miR-34a and miR-21 expression, suggesting that these miRNAs may be therapeutic targets of GLP1-RAs, improving liver steatosis, and supporting the hypothesis to utilize GLP1-RAs for NAFLD treatment (Table 1). Here, GCG is linked to metabolic dysfunction-associated steatotic liver disease.